Description: MEI Pharma, Inc., a development stage oncology company, focuses on the clinical development of therapeutics for the treatment of cancer. It develops various lead drug candidates, including ME-143 that has completed Phase I clinical trials in patients with refractory solid tumors; ME-344, an active metabolite of NV-128, which is in Phase I clinical trials in patients with solid refractory tumors; and Pracinostat, an orally histone deacetylase inhibitor that has completed various Phase I clinical trials in patients with hematologic disorders. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California. MEI Pharma, Inc. is a subsidiary of Novogen Limited. MEI Pharma, Inc. (NasdaqCM:MEIP) operates independently of Novogen Limited as of December 03, 2012.
Home Page: www.meipharma.com
MEIP Technical Analysis
11455 El Camino Real
San Diego,
CA
92130
United States
Phone:
858 369 7100
Officers
| Name | Title |
|---|---|
| Dr. Daniel P. Gold | Pres, CEO & Director |
| Mr. Brian G. Drazba B.A., CPA, CPA | CFO & Sec. |
| Mr. David M. Urso B.A., Esq., J.D. | COO & Gen. Counsel |
| Dr. Richard G. Ghalie | Chief Medical Officer |
| Ms. Virginia Sankey | VP of Fin. |
| Dr. Eric Deng Ph.D. | VP of Technical Operations |
| Ms. Tina Clark Beamon Esq., J.D. | Chief Compliance Officer |
| Mr. Eugene Park | VP of Marketing |
| Ms. Anne Frese | Chief People Officer |
| Dr. Robert D. Mass | Strategic Advisor |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.8394 |
| Price-to-Sales TTM: | 0.7835 |
| IPO Date: | 2003-12-19 |
| Fiscal Year End: | June |
| Full Time Employees: | 102 |